Arecor Therapeutics PLC (AREC) - Total Assets
Based on the latest financial reports, Arecor Therapeutics PLC (AREC) holds total assets worth GBX8.10 Million GBX (≈ $985.66 USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AREC cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Arecor Therapeutics PLC - Total Assets Trend (2017–2025)
This chart illustrates how Arecor Therapeutics PLC's total assets have evolved over time, based on quarterly financial data. See Arecor Therapeutics PLC (AREC) shareholders funds for net asset value and shareholders' equity analysis.
Arecor Therapeutics PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
Arecor Therapeutics PLC's total assets of GBX8.10 Million consist of 86.4% current assets and 13.6% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 37.0% |
| Accounts Receivable | GBX868.00K | 10.7% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX16.00K | 0.2% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Arecor Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Arecor Therapeutics PLC (AREC) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arecor Therapeutics PLC's current assets represent 86.4% of total assets in 2025, an increase from 74.0% in 2017.
- Cash Position: Cash and equivalents constituted 37.0% of total assets in 2025, down from 40.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 10.7% of total assets.
Arecor Therapeutics PLC Competitors by Total Assets
Key competitors of Arecor Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $260.53 Million |
Arecor Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.35 | 2.53 | 2.71 |
| Quick Ratio | 4.35 | 2.38 | 3.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX5.39 Million | GBX4.98 Million | GBX2.41 Million |
Arecor Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Arecor Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.04 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -7.1% |
| Total Assets | GBX8.10 Million |
| Market Capitalization | $275.63K USD |
Valuation Analysis
Below Book Valuation: The market values Arecor Therapeutics PLC's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Arecor Therapeutics PLC's assets decreased by 7.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arecor Therapeutics PLC (2017–2025)
The table below shows the annual total assets of Arecor Therapeutics PLC from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX8.10 Million ≈ $985.66 |
-7.12% |
| 2024-12-31 | GBX8.72 Million ≈ $1.06K |
-43.28% |
| 2023-12-31 | GBX15.38 Million ≈ $1.87K |
-29.35% |
| 2022-12-31 | GBX21.77 Million ≈ $2.65K |
+4.03% |
| 2021-12-31 | GBX20.92 Million ≈ $2.55K |
+388.38% |
| 2020-12-31 | GBX4.28 Million ≈ $521.21 |
-0.51% |
| 2019-12-31 | GBX4.31 Million ≈ $523.87 |
-21.01% |
| 2019-05-31 | GBX5.45 Million ≈ $663.21 |
+163.75% |
| 2018-05-31 | GBX2.07 Million ≈ $251.46 |
-19.39% |
| 2017-05-31 | GBX2.56 Million ≈ $311.93 |
-- |
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a no… Read more